Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | MMP12 | P39900 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7349545 | 0.88 | ALDH1A1 (0.52) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL13185528 | 0.86 | ALDH1A1 (0.62) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL532793 | 0.86 | GAA (0.71) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL31189953 | 0.86 | ALDH1A1 (0.69) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL3443973 | 0.86 | ALDH1A1 (0.69) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL13932097 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL4263597 | 0.85 | ALDH1A1 (0.60) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL24125014 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL4295545 | 0.84 | ALDH1A1 (0.71) | ALDH1A1MAPTPKMGAAMMP12 | |
| SCHEMBL13164180 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPTPKMGAAMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251370-B2 | Small molecule inhibitors of the BfrB:Bfd interaction | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| CN-114256491-A | Polymer electrolyte membrane, method for producing same, and solid polymer fuel cell | 东丽先端材料研究开发（中国）有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS | 2022-02-03 | — | — | US | disclosed |
| WO-2020117832-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | UNIVERSITY OF KANSAS (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3661990-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M Innovative Properties Company (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019027746-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-9522906-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9115151-B2 | Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof | ABBVIE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004041810-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004041814-A1 | HETEROARYL-PYRAMIDINE DERIVATIVES AS JAK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097504-A1 | Compositions useful as inhibitors of jak and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-05-20 | — | — | US | disclosed |
| EP-1392644-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-04 | — | — | US | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| WO-2002096858-A1 | CINNAMIDE DERIVATIVES AS KCNQ POTASSIUM CHANNEL MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | ALDH1A1 4417/4885MAPT 4627/4885PKM 3844/4885 |
| US-12251370-B2 | Small molecule inhibitors of the BfrB:Bfd interaction | BLVRB, TFPI, ETFB | ALDH1A1 2584/4885MAPT 4314/4885PKM 4379/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | ALDH1A1 1893/4885MAPT 2525/4885PKM 3106/4885 |
| US-20030166650-A1 | Cinnamide derivatives as KCNQ potassium channel modulators | KCNH2, KCNH3, KCNQ1 | ALDH1A1 2914/4885MAPT 4835/4885PKM 1306/4885 |
| US-20040097504-A1 | Compositions useful as inhibitors of jak and other protein kinases | JAK1, JAK2, JAK3 | ALDH1A1 3261/4885MAPT 2988/4885PKM 991/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | ALDH1A1 4417/4885MAPT 4627/4885PKM 3844/4885 |
| US-20220031661-A1 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | BLVRB, TFPI, ETFB | ALDH1A1 2584/4885MAPT 4314/4885PKM 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.